Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines

@article{Zuckerman2006ProtectiveEI,
  title={Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines},
  author={Jane N. Zuckerman},
  journal={Journal of Medical Virology},
  year={2006},
  volume={78}
}
  • J. Zuckerman
  • Published 1 February 2006
  • Biology, Medicine
  • Journal of Medical Virology
Hepatitis B vaccines are highly effective and safe and have been incorporated into national immunization programs in over 150 countries. The major humoral immune response is to the common a determinant of the surface antigen protein of the virus. Approximately 5–10% of healthy immunocompetent subjects do not mount an antibody response (anti‐HBs). Non‐response is associated with different HLA‐DR alleles and impaired Th cell response, among other factors such as route of injection, age, gender… 
HEPATITIS B VACCINE: IMMUNITY, EFFICACY AND TYPES
TLDR
Investigation is needed to assess factors that can impede an adequate antibody response, HBV variants, and the need for booster doses to preserve vaccine-induced immunity, vaccinating schedule for older children, evaluation of those vaccinated but in persistent contact in HBV-endemic areas.
On DNA vaccines and prolonged expression of immunogens
  • T. Hanke
  • Biology, Medicine
    European journal of immunology
  • 2006
TLDR
This commentary discusses the results of immunization of BALB/c mice intramuscularly with a DNA vaccine encoding HBsAg, the safety of plasmid DNA‐vectored genetic vaccines in general, the use of DNA vaccines expressingHBsAg for the treatment of chronic hepatitis and the consequences of prolonged immunogen expression for the development of protective immune responses.
Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S Vaccine
TLDR
Sci-B-Vac is a mammalian cell-derived recombinant Pre-S1/Pre-S2/S hepatitis B vaccine which has been shown to be highly immunogenic, inducing faster and higher seroprotection rates against HBV with higher anti-HBs levels at lower HBsAg doses as compared to conventional yeast-derived vaccines.
Studies on Hepatitis B Vaccination and Factors Associated with the Vaccine Response
TLDR
Revaccination of nonresponders to the standard hepatitis B vaccine regimen with a double dose of the combined hepatitis A and B vaccine was highly effective, most likely explained by the increased dose, a positive bystander effect conferred by the hepatitis A vaccine, or both.
Impact of the Immunogen Nature on the Immune Response against the Major HBV Antigens in an HBsAg and HLA-humanized Transgenic Mouse Model
TLDR
Results indicate that cellular immune responses necessary for the development of protective immunity can be achieved by DNA or protein immunization, however, important differences in their nature arise when immunogens are administered several times.
Vaccination against hepatitis A and B: developments, deployment and delusions
  • J. Zuckerman
  • Medicine, Biology
    Current opinion in infectious diseases
  • 2006
TLDR
Further evidence is described to support the introduction of universal immunization against hepatitis B in those countries where this has yet to be implemented and the administration of polyvalent vaccines in order to best protect populations against infectious diseases.
Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization.
TLDR
A notable proportion of fully vaccinated adolescents had lost immune memory conferred by a plasma-derived HB vaccine 15-18 years later, which may raise concerns about the need for a booster vaccine for high-risk groups in the long run.
A Vesicular Stomatitis Virus-Based Hepatitis B Virus Vaccine Vector Provides Protection against Challenge in a Single Dose
TLDR
A recombinant vesicular stomatitis virus (VSV)-based vaccine vector expressing the HBV middle envelope surface protein (MS) was found to efficiently generate a strong HBs-specific antibody response following a single immunization in mice.
Evaluation of ISCOM vaccines for mucosal immunization against hepatitis B
TLDR
Potential of ISCOMs in their use as a carrier adjuvant for nasal subunit vaccines against hepatitis B is demonstrated by producing humoral, cellular and cellular immune responses upon nasal administration although high and multidose administrations were required to elicit potent immune responses.
New Advances in Hepatitis B Vaccination for Adults
TLDR
This review seeks to update readers on the performance of the current second-generation vaccine and the challenges including primary and secondary vaccine failure, as well as compliance and coverage.
...
...

References

SHOWING 1-10 OF 29 REFERENCES
Recombinant hepatitis B triple antigen vaccine: Hepacare®
TLDR
The inclusion of pre-S1 and -S2 components of hepatitis B surface antigen in addition to the single antigen (triple antigen) in a novel vaccine, Hepacare®, Medeva Pharma Plc, Speke, UK, overcomes nonresponsiveness and hyporesponsiveness in a significant number of individuals.
DNA‐based immunotherapy: potential for treatment of chronic viral hepatitis?
TLDR
This review focuses on immunological aspects of chronic HBV and HCV infection and on the potential of DNA‐ and DC‐based vaccines for the treatment of chronic viral hepatitis.
A pilot study of the CY‐1899 T‐cell vaccine in subjects chronically infected with hepatitis B virus
TLDR
Administration of the single‐epitope vaccine, CY‐1899, initiated CTL activity, but of a magnitude lower than that observed during spontaneous HBV clearance, and this low‐level C TL activity was not associated with viral clearance.
The immune response to hepatitis B vaccine in humans: inheritance patterns in families
TLDR
Responsibility to the HBsAg vaccine is MHC linked, and inherited in a dominant fashion; an abnormal or missing immune response (Ir) gene is a characteristic of most examples of the extended haplotype [HLA- B8,SC01,DR3]; and other haplotypes also have abnormal orMissing Ir genes forHBsAg.
Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin‐2 in patients with chronic hepatitis B
TLDR
The preliminary data from this study demonstrate that the HBV surface antigen vaccine in combination with antiviral or immunomodulating drugs induced antiviral immune responses and consequently viral elimination may be achieved in patients with unfavorable prognosis.
Genetic prediction of nonresponse to hepatitis B vaccine.
TLDR
It is concluded that the usual response to hepatitis B surface antigen is due to the presence of a dominant immune-response gene in the MHC and that a low response isdue to the absence of such a gene and the presence on both chromosomes of MHC haplotypes that indicate such a response.
...
...